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Objective: To compile a comprehensive summary of published human experience
with levodopa given intravenously, with a focus on information required by regulatory
agencies.
Background: While safe intravenous (IV) use of levodopa has been documented for
over 50 years, regulatory supervision for pharmaceuticals given by a route other than
that approved by the U.S. Food and Drug Administration (FDA) has become increasingly
cautious. If delivering a drug by an alternate route raises the risk of adverse events, an
investigational new drug (IND) application is required, including a comprehensive review
of toxicity data.
Methods: Over 200 articles referring to IV levodopa were examined for details of
administration, pharmacokinetics, benefit, and side effects.
Results: We identified 142 original reports describing IVLD use in humans, beginning
with psychiatric research in 1959–1960 before the development of peripheral
decarboxylase inhibitors. At least 2760 subjects have received IV levodopa, and reported
outcomes include parkinsonian signs, sleep variables, hormone levels, hemodynamics,
CSF amino acid composition, regional cerebral blood flow, cognition, perception and
complex behavior. Mean pharmacokinetic variables were summarized for 49 healthy
subjects and 190with Parkinson’s disease. Side effects were those expected from clinical
experience with oral levodopa and dopamine agonists. No articles reported deaths or
induction of psychosis.
Conclusion: At least 2760 patients have received IV levodopa with a safety profile
comparable to that seen with oral administration.
Keywords: levodopa, intravenous, Parkinson, DOPA, pharmacokinetics, carbidopa, FDA, IND
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INTRODUCTION
Impairments in dopaminergic neurotransmission in the basal
ganglia are a hallmark of Parkinson disease (PD), the secondmost
common neurodegenerative disease. Replacement of dopamine
has been the cornerstone of treatment for PD. Because dopamine
itself does not cross the blood-brain barrier (BBB), its immediate
precursor levodopa (L-3,4-dihydroxphenylalanine, L-DOPA) is
administered since it crosses the BBB (Hornykiewicz, 1963;
Cotzias et al., 1967; Birkmayer and Hornykiewicz, 2001).
Although purified levodopa was first ingested by mouth in 1913
(Roe, 1997), it was first used formedical treatment by intravenous
(IV) rather than oral administration (Pare and Sandler, 1959;
Birkmayer and Hornykiewicz, 2001).
Oral levodopa has become the preferred method of treatment
clinically, but IV levodopa administration still holds advantages
over the oral form for some purposes. First, the rapid
administration of IV levodopa is often necessary for certain
study designs, including those focused on the pharmacokinetics
and pharmacodynamics of the drug. Additionally, the IV route
leads tomore predictable plasma levodopa concentration because
oral medications have highly variable absorption characteristics,
especially in PD patients (Bushmann et al., 1989), with
differences in absorption based on sex and age (Robertson
et al., 1989; Kompoliti et al., 2002). IV administration also
permits researchers to keep brain levodopa concentrations
constant while assessing physiological responses over time.
Recent years have seen increasing interest in potential benefits
of continuous dopaminergic stimulation in the treatment of
PD (Jenner et al., 2011). Continuous stimulation helps avoid
wearing off of motor benefit during levodopa nadirs, and
there is also some evidence that it may reduce the risk of, or
mitigate, dyskinesias and other peak-dose side effects. Thus,
IV levodopa may prove useful for human studies investigating
the pathophysiology of continuous vs. pulsatile dopaminergic
stimulation in humans. Finally, IV levodopa is sometimes used
clinically in patients who cannot tolerate oral medications,
such as PD patients during surgery or on total parenteral
nutrition.
Current U.S. FDA regulations focus heightened scrutiny on
research in which drugs are delivered by a route for which the
drug has not been approved. Predictably, in addition to any safety
benefits, the heightened scrutiny has created practical obstacles
to research with IV levodopa, as described for instance by
Rascol et al. (2001, p. 250). Specifically, an IND (Investigational
New Drug) application must be submitted if the risks of IV
administration significantly exceed those of oral levodopa [§21
CFR 312.2(b)(iii)]. Therefore, the overall goal of this paper
is to determine whether or not IV levodopa carries risks
greater than oral administration by compiling a literature review
that comprehensively summarizes the human experience with
intravenously administered levodopa. We tabulate the extent of
human exposure, side effects, benefits, and efficacy. We also
summarize pharmacokinetic (PK) and pharmacodynamic (PD)
parameters from these studies. These data should help inform
decisions about whether IV administration of levodopa requires
an IND.
METHODS
The authors searched MEDLINE and OVID, reviewed selected
books, searched toxicity databases, and followed references cited
in those sources. Articles written completely in languages other
than English, French, German, Italian, Spanish, or Portuguese
were excluded. Search terms included (levodopa/L-dopa/DOPA)
AND (intravenous/intravascular/infusion/injection/i.v.); limit to
humans; search date through May, 2015. Studies using oral or
intraduodenal l-DOPA administration were excluded except for
PK/PD studies cited in Table 2. Studies in which IV levodopa
was always coadministered with monoamine oxidase inhibitors
(MAOIs) or catechol-O-methyltransferase (COMT) inhibitors
were excluded. Levodopa methyl ester (Juncos et al., 1987) and
d,l-DOPA (Pare and Sandler, 1959) were included, but PK/PD
calculations were corrected for the difference in molecular
weights. Co-administered drugs were reported if included by the
authors.
We recorded total dose and maximum infusion rate. We
also recorded pharmacokinetic (PK) and pharmacodynamic
(PD) parameters where available, including steady state volume
of distribution (VOD), clearance, distribution half life (t½α),
elimination half life (t½ or t½β), Emax, and EC50. Reported
data were used to calculate any missing PK parameters where
possible. Additionally, any reports on efficacy were noted. Side
effect frequency was recorded if reported. The number of subjects
and subject conditions (Parkinson disease, other disease states
or healthy volunteers) were recorded for each study. Average
PK parameters were calculated across studies, weighted by the
number of subjects.
RESULTS
One hundred forty-two articles reporting intravenous levodopa
administration were identified. Most subjects with parkinsonism
were diagnosed with idiopathic PD, but some studies reported
a variety of etiologies including postencephalitic and vascular
parkinsonism and PSP. PD patients differed in their history
of prior drug treatment before the studies with conditions
including de novo, fluctuating, on-off, and stable. Some subjects
were treated with levodopa for conditions other than PD
(see Table 1: Patient Populations and Response Parameters),
including other movement disorders (dystonia, progressive
supranuclear palsy [PSP], neuroleptic malignant syndrome
[NMS], primary psychiatric disorders (schizophrenia, mood
disorders, personality disorders), endocrine disorders (diabetes
mellitus, essential obesity, hypopituitarism), hepatic disease
(alcoholic cirrhosis, steatohepatitis, hepatic encephalopathy),
cardiac valvular disease, and asthma. Healthy controls were also
included in some studies.
Pharmacokinetic data were reported for a total of 251
human subjects (see Table 2: Pharmacokinetics of Levodopa).
Co-administration of a peripheral decarboxylase inhibitor (PDI)
lowered the clearance and increased the elimination half-life
of intravenously administered levodopa, while there was no
notable effect of PDIs on volume of distribution. Additional
PK data are available from studies that gave levodopa by
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TABLE 1 | Patient populations and response parameters.
Patient populations Response parameters
Healthy volunteers Vital signs:
Movement disorders: Heart rate, blood pressure,
temperature, respirationsParkinson’s (de novo, stable,
fluctuators, on-off) Cardiovascular:
Progressive supranuclear palsy ECG
Parkinson’s disease psychosis Cerebral blood flow
Carcinoma of the rectum Renal:
Stereotactic surgery Urine flow
Post-menopausal women Urinary sodium excretion
Tourette syndrome/tic disorders Potassium excretion
Asthma Plasma renin activity
Schizophrenia Renal plasma flow
Mood disorders: Metabolism:
Mild to moderate depression Urinary metabolite excretion
Treatment-resistant depression Cerebral metabolism
Bipolar depression Plasma metabolites
Cyclothymic disorder CSF amino-acid composition
Borderline personality disorder PD motor improvement
Neuroleptic malignant
syndrome
Unified Parkinson’s disease rating
scale (UPDRS), walking, tapping, etc.
Hepatic disorders: Dyskinesias







Cardiovascular disease: EEG (including REM sleep EEG)
Atrial septal defect Endocrine:
Rheumatic valvular disease Prolactin, HGH, ACTH, LH,
vasopressin
Subject populations given IV levodopa and responses to drug measured in studies listed
in Table 3.
other routes (Sasahara et al., 1980a; Poewe, 1993; Muhlack
et al., 2004; LeWitt et al., 2009), and several studies report
the bioavailability of oral doses relative to IV administration
(Sasahara et al., 1980b; Robertson et al., 1989; Kompoliti et al.,
2002).
The pharmacodynamic data (see Table 3: Reports of Human
Experience with IV Levodopa) represent a total of 2760 human
subjects, with a significant variety of patient groups and a
multitude of response parameters (see Table 1). No side effects
were reported for 1260 subjects. The highest total IV dose was
4320mg in 1 day, given to a patient with idiopathic PD and
carcinoma of the retina. The patient reported no adverse effects
at this dose. The highest reported single bolus dose was 200mg,
and the highest infusion rate was 5.0mg/kg/h.
Concomitantly administered peripheral decarboxylase
inhibitors included carbidopa and benserazide. PDIs affected
clearance and volume of distribution (as mentioned above),
minimized gastrointestinal symptoms, and allowed subjects
to be given lower doses of levodopa. Other concomitant
drugs are listed, to help explain any side effects that might
be caused by concomitant drug administration or an
interaction with levodopa rather than by levodopa alone.
These include adenosine receptor antagonists (istradefylline,
tozadenant [SYN115], aminophylline, caffeine), stimulants
(amphetamines, methylphenidate), dopamine receptor agonists
(apomorphine, terguride, SKF38393), monoamine oxidase
(MAO) inhibitors, dextromethorphan, estradiol, paroxetine, and
dantrolene.
A variety of neurological, psychiatric, cardiovascular, and
other physiological effects of levodopa were monitored (see
Table 1). There were no reported deaths. There were no
instances of psychosis, even when attempting to elicit it in
susceptible subjects (Goetz et al., 1998). There were also no
life-threatening events (serious adverse effects) following IV
levodopa administration at high doses, regardless of whether
a PDI was co-administered. With co-administration of a PDI,
the dosage range causing side effects (mainly nausea and
asymptomatic hypotension) was 45–150mg as a single bolus
or infusions of 0.5–2.0mg/kg/h. Without a co-administered
PDI, side effects were reported with a bolus of 60–200mg or
an infusion of 1.5–3.0mg/kg/hr. Side effects were more likely
with higher doses, but other factors such as age, sex, disease
severity, and prior treatment also played a role in side effects of
levodopa.
Other than these side effects found at high doses, several
milder or less frequent side effects were reported. These
primarily included mild autonomic changes (orthostasis
and tachycardia), psychiatric changes (sedation, anxiety,
insomnia, and improvement in mood), and neurologic effects
(improvements in tics, REM sleep changes, subjective weakness,
headaches, and increased dyskinesias). Various other effects were
noted in isolated reports (listed in Table 3). It is important to
note that both side effects and efficacy depended strongly on
subject factors including gender, age, past treatment, and disease
state. Also, dsykinesia was mentioned as a side effect only in
patients with PD, and most often in those with a long history of
previous levodopa treatment.
Motor benefits of levodopa in PD have been demonstrated
conclusively. Additional reported benefits of IV levodopa
treatment in PD included improved sleep (Hardie et al.,
1984) and attenuation of early morning akinesia or dystonia
(Juncos et al., 1987). In other patient groups, benefits of
IV levodopa included improvement of the comatose state in
hepatic encephalopathy (Abramsky and Goldschmidt, 1974)
and improvement in depressive and somatoform symptoms
(Ingvarsson, 1965a). One report found it more effective
than dantrolene for treating neuroleptic malignant syndrome
(Nisijima et al., 1997). More recently, IV levodopa treatment
was found to alleviate the neuropsychiatric adverse effects
associated with interferon-alpha, namely lethargy, hypersomnia,
depression, agitation, akathisia, and confusion (Sunami et al.,
2000).
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TABLE 2 | Pharmacokinetics of levodopa.
References Patient group Clearance Volume of Elimination Distribution Oral
distribution half-life half-life bioavailability
n Mean (L/kg/h) n Mean (L/kg) n Mean (h) n Mean (h) n Mean (unitless)
Birkmayer et al., 1973 PD 50 1.61 50 2.44 50 1.05
Bredberg et al., 1990 Fluctuating 5 0.37
Chan et al., 2004 De novo 12 0.36 12 0.63 12 2.25 12 0.17
Chronic 12 0.35 12 0.49 12 1.47 12 0.17
Durso et al., 2000 “Slow” CD absorption 5 1.18
“Rapid” CD absorption 4 1.15
Fabbrini et al., 1987 De novo 4 0.13 4 0.26 4 1.44
Stable 6 0.11 6 0.22 6 1.41
Wearing-Off 6 0.13 6 0.30 6 1.67
On-off 12 0.13 12 0.30 12 1.54
Hardie et al., 1986a Fluctuating 7 1.14 7 2.63 7 1.60 7 0.13
Gancher et al., 1987b De novo 5 0.34 5 0.56 5 1.70 5 0.10
Stable 4 0.33 4 0.62 4 1.80 4 0.11
Fluctuating 11 0.32 11 0.65 11 2.00 11 0.10
Nutt et al., 1985 2 h IV 7 0.55 7 0.67 7 1.38 7 0.07
(all PD, fluctuating) 2 h IV + PDI 7 0.30 7 0.80 7 2.01 7 0.11
≥20 h IV 4 0.52 4 0.88 4 1.19 4 0.11
≥20 h IV + PDI 4 0.28 4 1.09 4 2.60 4 0.33
Nutt et al., 1992 De novo 8 0.44 8 0.75 8 1.60
Stable 12 0.42 12 0.75 12 1.70
Fluctuating 9 0.39 9 0.63 9 1.50
Poewe, 1993e PD 1.40 3.00 1.50 0.09
Roberts et al., 1995c,d Healthy 8 0.37 8 1.13 8 2.15
Healthy + selegine 8 0.37 8 2.01 8 3.78
Robertson et al., 1989c Healthy elderly 9 0.85 9 1.01 9 0.82 9 0.63
Healthy young 8 1.40 8 1.65 8 0.82 8 0.41
Healthy elderly + PDI 8 0.35 8 0.62 8 1.23 8 0.85
Healthy young + PDI 8 0.56 8 0.93 8 1.16 8 0.86
Sasahara et al., 1980bf PD 5 1.38 5 1.29 5 0.65 5 0.33
Stocchi et al., 1992 Intravenous bolus 6 0.97 6 0.96 6 0.83
(all “on-off”) Intravenous infusions 2 0.63 2 0.82 2 0.90
Total n 212 242 251 73 16 (PDI) 22 (no PDI)
Weighted mean 0.719 L/kg/h 1.18 L/kg 1.50 h 0.14 h 0.86 (PDI) 0.48 (no PDI)
Summary of pharmacokinetic parameters with weighted means.
aAssumed mean weight to be 70 kg for VOD.
bValues read from graphs.
cHalf-life estimated from relationship: clearance = (ln 2 * VOD)/ elim. T1/2.
dAssumed mean weight to be 70 kg for clearance.
eFrom a table with no additional data provided; not included in weighted mean calculations of pharmacokinetic parameters.
fVOD estimated from relationship: clearance = (ln 2 * VOD)/ elim. T1/2.
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DISCUSSION
The existing literature strongly supports the safety of IV
levodopa, which has been used in humans for more than half
a century (Pare and Sandler, 1959). IV levodopa has been
administered to over 2700 human subjects. Despite infusion rates
as high as 5.0mg/kg/h and boluses as large as 200mg, there are
no recorded instances of death or of other serious adverse effects
of IV levodopa, nor have there been documented cases of other
serious side effects, such as psychosis, that might limit its use in
humans. Milder side effects, the most significant of which are
nausea and vomiting, were most prominent with rapid infusions
in the range of 1–2mg/kg or 100–200mg over less than 15min
(Bruno and Bruno, 1966; Fehling, 1966; Rinne and Sonninen,
1968; Moorthy et al., 1972; Quinn et al., 1984; Black et al., 2003).
These conclusions are supported by safety data from other
species. The Registry of Toxic Effects of Chemical Substances
reports the lowest published toxic dose of levodopa in any non-
human species as 2.5mg/kg, referring to a subtle behavioral effect
on a learning measure in a mouse (NIOSH and Biovia, 2015)1.
The lowest IV levodopa dose that was lethal to half of subjects
(LD50) was “>100mg/kg” in rats. In mice, the LD50 ranges
from 450mg/kg (administered intravenously) to 4449mg/kg
(administered subcutaneously). Typical human doses are in the
range of only 1mg/kg; thus, human studies with IV levodopa
administer doses substantially lower than those dangerous to
nonhuman mammals.
In summary, IV levodopa has similar efficacy and side
effects as oral levodopa (Connolly and Lang, 2014) and
dopamine agonists (Bonuccelli and Ceravolo, 2008). These
include gastrointestinal (nausea, vomiting, and abdominal
discomfort) and neuropsychiatric effects (sedation, dyskinesias).
Nausea and orthostatic hypotension, side effects of both IV and
1RTECS reported the lowest toxic dose as “100 µg/kg,” but the dose in the cited
reference was actually 100 µg/g= 100mg/kg (Takahara et al., 1980).
oral levodopa, are largely blocked by PDIs and are less common
in patients accustomed to dopamimetic treatment. The other side
effects are infrequent and neither serious nor life-threatening
(Connolly and Lang, 2014). When given with adequate PDI
pretreatment, IV levodopa has minimal if any cardiovascular
effects (Siddiqi et al., 2015).
The safety of IV levodopa is important for patients but also
for regulatory review. Changing the route of administration
of any drug in a study traditionally necessitates submitting
an IND application if changing the route of administration
“significantly increases the risks . . . associated with the use
of the drug product” [§21 CFR 312.2(b)(iii)]. The data from
our review of the literature suggest that IV administration of
levodopa does not significantly increase the associated risks of
levodopa in comparison to oral administration. In summary,
studies conducted throughout the past half century support the
safety of IV levodopa administration in human patients.
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